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Background: Polycystic ovary syndrome (PCOS) is a complex multifactor disorder and genetic factors have been
implicated in its pathogenesis. Our previous genome-wide association study (GWAS) had identified allele frequencies in
several single nucleotide polymorphisms (SNPs) in gene USP34 (Ubiquitin-Specific Protease 34) were significantly
different between PCOS cases and controls. This study was aimed to replicate the previous results in another
independent cohort.
Methods: One thousand two hundred eighteen PCOS cases and 1057 controls were recruited. Genotyping of
two SNPs (rs17008097 and rs17008940) in USP34 gene were performed by TaqMan-MGB probe assay and
genotype-phenotype analysis was conducted subsequently.
Results: The differences of allele or genotype frequencies were not significant statistically between PCOS and
controls, even after age and BMI adjustment. For clinical and metabolic features (LH, T and HOMA-IR) analysis in
PCOS cases, no statistical differences among three genotypes of rs17008097 and rs17008940 were found. However,
rs17008940 was shown to be slightly associated with BMI in PCOS cases rather than in controls, even after age
adjustment (TC vs CC P = 0.006, OR = 1.042, 95% CI 1.012–1.073; TT vs CC P = 0.037, OR = 1.050, 95% CI 1.003–1.100).
Conclusions: USP34 gene polymorphisms (rs17008097 and rs17008940) may not be associated with PCOS in the Han
Chinese women.
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Polycystic ovary syndrome (PCOS) is a kind of reproductive
and metabolic disorder characterized by hyper-androgen
and insulin resistance, which affects 6–8 % of reproductive-
aged women in Caucasian and 5.6 % in Chinese [1–3].
Clinical diagnosis of PCOS is made on the basis of at least
two following criteria after excluding other related diseases:
oligo- or anovulation, clinical or biochemical hyperandro-
genism and polycystic ovaries under ultrasound [4]. The
etiology of PCOS is not well understood yet. However, it’s
now widely accepted that genetic factors play an indis-
pensable role in the development of PCOS [5] and several* Correspondence: hanzh80@yahoo.com
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unless otherwise stated.candidate genes have been reported recently [6, 7]. We
performed the first GWAS for PCOS which followed by
replication studies only for SNPs with p value less than
10e-6, and finally identified three susceptibility loci
(2p16.3, 2p21 and 9q33.3) [6]. However, other loci with
p value around 10e-5 in GWAS, such as SNPs in gene
USP34, remain intriguing and might also be potential
risk factors of PCOS.
The USP34 gene is located on chromosome 2p15 and
encodes a kind of deubiquitinating enzyme, which belongs
to ubiquitin-specific protease family. Data obtained from
COSMIC database [8] shows that somatic variations of
USP34 are related to ovary tumor. Moreover, USP34 posi-
tively regulates Wnt signaling pathway [9], which plays an
important role in gender differentiation, folliculogenesis,
ovulation and other biological processes in reproduction
[10]. The expression patterns of several genes in Wnt
pathway are altered in PCOS (such as DKK1, a negativehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of PCOS cases and controls
PCOS Control p value
Age (years) 28.55 ± 3.72 31.84 ± 4.74 <0.001
BMI (kg/m2) 25.12 ± 4.35 22.78 ± 3.25 <0.001
LH (IU/L) 10.03 ± 5.93 4.76 ± 2.23 <0.001
T (ng/dl) 51.69 ± 21.00 42.35 ± 18.46 <0.001
BMI: body mass index; LH: Luteinizing hormone; T: testosterone
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is assumed that USP34 may also have relationship with
PCOS. As an extension of GWAS, here we conducted
an independent case-control replication study to evaluate
the association between USP34 and PCOS susceptibility.
Methods
This study was approved by Institutional Review Board
for Reproductive Medicine of Shanghai Jiaotong University
and Shandong University. A total of 1218 PCOS cases and
1057 unrelated controls were recruited consecutively from
2009 to 2013 at the Center for Reproductive Medicine,
Renji Hospital, School of Medicine, Shanghai Jiaotong
University and the Center for Reproductive Medicine,
Provincial Hospital Affiliated to Shandong University.
Among them, 94 PCOS cases, also born from Northern
China, were collected at Renji Hospital from 2012 to
2013. Signed informed consent was obtained from each
participant of this study.
PCOS diagnosis was based on the 2003 Rotterdam
PCOS consensus criteria and other related diseases (such
as congenital adrenal hyperplasia, Cushing’s syndrome,
androgen-secreting tumors, thyroid disease and hyperpro-
lactinaemia) were excluded. In detail, PCOS can be diag-
nosed if at least two of the following three features are
met: oligo- or anovulation, clinical and/or biochemical
signs of hyperandrogenism and polycystic ovaries. Oligo-
or anovulation was referred to menstrual cycles of more
than 35 days in length or a history of ≤ 8 menstrual cycles
in a year [1]; polycystic ovaries was defined as the pres-
ence of at least one ovary >10 ml or at least 12 follicles
2–9 mm in diameter by transvaginal ultrasound [4].
Hyperandrogenism was the presence of hirsutism (Ferriman-
Gallwey score ≥ 6) [14] or serum total testosterone ≥ 60 ng/dl
[15]. The inclusion criteria for the control group were
as follows: normal menstrual cycles, no hyperandrogenism
and no polycystic ovaries (PCO) under ultrasound. All indi-
viduals who were taking medications such as oral contracep-
tives and metformin during last 3 months were excluded.
Biochemical measurements
Serum luteinizing hormone (LH) and testosterone (T) levels
of subjects were measured by a chemiluminescent analyser
(Beckman Access Health Company, Chaska, Minnesota,
USA). The plasma glucose was measured by AU640 auto-
matic biochemistry analyser (Olympus Company, Hamburg,
Germany) and insulin was measured by chemiluminescent
analyzer. Insulin resistance was calculated as fasting glucose
(mmol/L)*fasting insulin (mIU/L)/22.5 using homeostasis
model assessment (HOMA-IR).
SNP selection
SNPs in USP34 were selected for replication study accord-
ing to the following criteria: SNPs that exist in AffymetrixGenome-Wide Human SNP Array 6.0 (Affymetrix, Santa
Clara, CA, USA); can stand for a block; minor allele fre-
quency (MAF) > 5 % in Chinese Han population; statis-
tically different (P < 10e-4) from our previous GWAS
(see Additional file 1, Table S1); r2 of selected SNPs < 0.8.
Ultimately, rs17008097 and rs17008940 were selected to
precede further replication study.
SNP genotyping
Genomic DNA was extracted from whole peripheral blood
using QIAamp DNA mini kit (Qiagen, Hilden, Germany).
Genotyping of SNPs was carried out by TaqMan-MGB
probe assay (Invitrogen Trading, Shanghai, China), probes
and primers were shown in Additional file 1, Table S2.
Then, 5 % of the samples were randomly selected for direct
sequencing to validate the genotyping assays.
Statistical analysis
Numerical variables of clinical characteristics of PCOS
cases and controls were expressed as mean ± SD. Hardy-
Weinberg equilibrium (HWE) and linkage disequilibrium
(LD) tests were performed by Haploview software. The
case-control genetic power was analyzed by Genetic Power
Calculator [16]. A sample size > 721 PCOS cases (case:
control = 1) would provide 80 % power (α = 0.05), assum-
ing higher risk allele frequency (A) of 0.05 and a genotype
relative risk (Aa) of 1.5. Frequencies of genotype and allele
between PCOS subjects and controls were compared by
Pearson Chi-square test, and the p value was adjusted
by logistic regression to eliminate the effect of age and
body mass index (BMI) using SPSS v.19.0 (SPSS Inc.,
Chicago, IL, USA). P < 0.05 was considered statistically
significant.
For genotype-phenotype analysis in PCOS patients,
additive model (+/+ vs +/− vs −/−) was selected after
comparison; one-way analysis of variance (ANOVA) test
was used for phenotype comparison among different
genotypes. Linear regression was used for age and BMI
adjustment. Conservative Bonferroni test was used for
multiple testing corrections.
Results
As shown in Table 1, the PCOS group was younger than
the controls (P < 0.001). In addition, PCOS group had
higher BMI, LH level and T level than the control group
Table 2 Genotype and allele frequencies of USP34 in PCOS and controls
PCOS Control P P adjusted OR/95 % CI
rs17008097 Genotype CC 548(45 %) 484(45.8 %) 0.807 0.791
GC 531(43.6 %) 447(42.3 %)
GG 139(11.4 %) 126(11.9 %)
Allele C 1627(66.8 %) 1415(66.9 %) 0.918 0.791 0.993 (0.878–1.124)
G 809(33.2 %) 699(33.1 %)
rs17008940 Genotype CC 575(47.2 %) 505(47.8 %) 0.948 0.862
TC 513(42.1 %) 438(41.4 %)
TT 130(10.7 %) 114(10.8 %)
Allele C 1663(68.3 %) 1448(68.5 %) 0.869 0.862 0.990 (0.873–1.122)
T 773(31.7 %) 666(31.5 %)
P adjusted: adjust the p value by age and BMI; OR: Odd Ratio; CI: Confidence Interval
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hyperandrogenism and oligo-anovulation (HA + OA,
9.44 %), 10 patients present with hyperandrogenism and
polycystic ovaries (HA + PCO, 1.05 %), 620 patients
present with oligo-anovulation and polycystic ovaries
(HA + PCO, 65.06 %), and 233 patients present with
full-phenotype (HA + OA + PCO, 24.45 %).
The genotype frequencies of the two polymorphisms
in PCOS cases and controls were all in Hardy-Weinberg
equilibrium (P > 0.05). Genotype and allele frequencies
were summarized in Table 2 and no significant differ-
ences were observed between PCOS and controls. After
age and BMI adjustment with logistic regression, no as-
sociation was found. The minor allele frequencies (MAF)
of the 2 SNPs in four subgroups of PCOS were further an-
alyzed. No significant differences of MAF were observed
between each subgroup of PCOS and controls in the
present study (see Additional file 1, Table S3). Addition-
ally, there was no statistical difference among three gen-
etic models (additive, dominant and recessive) in genotype
analysis (see Additional file 1, Table S4), thus additive
model of genotype was selected for subsequent phenotype
analysis.
In genotype-phenotype analysis, clinical and metabolic
features were compared among different genotypes in
PCOS subjects, rs17008940 was shown to be associated
with BMI (P = 0.028) (Table 3), however, the association
was not significant after Bonferroni correction for multipleTable 3 Clinical and metabolic characteristics of PCOS cases in rs17
Characteristics CC(n = 575) TC(n = 513)
Age (years) 28.83 ± 3.73 28.39 ± 3.72
BMI (kg/m2) 24.740 ± 4.29 25.418 ± 4.34
LH (IU/L) 9.999 ± 6.08 10.028 ± 5.88
T (ng/dl) 51.17 ± 20.73 51.74 ± 21.41
HOMA-IR 2.62 ± 2.62 2.70 ± 2.12
HOMA-IR: homeostasis model assessment; P adjusted: adjust the p value by age antesting. The average level of BMI in TC and TT group was
higher than that in CC group after age adjustment (TC vs
CC P = 0.006, OR = 1.042, 95 % CI 1.012–1.073; TT vs
CC P = 0.037, OR = 1.050, 95 % CI 1.003–1.100). But in
control group, no significant difference was found in BMI
among the three genotypes of rs17008940 (P = 0.256).
Additionally, there were no significant differences in LH,
T or HOMA-IR among the PCOS cases carrying different
genotypes of the two SNPs, even after age and BMI adjust-
ment (Table 3, Table 4).
Discussion
As a powerful technique, GWAS shed new light on gen-
etic study for complex diseases. GWAS data is obtained
from computing and statistical analyses following SNP
chips detection, so the results are bioinformatics rather
than biological. However, GWAS itself owns some limi-
tations and it is necessary to be validated through further
replication studies. In general, p value of 5*10e-8 was used
as significant level for random variations in case-control
GWAS with a power of 0.8 [17, 18]. In our previous
GWAS, only SNPs with p value < 10e-6 were replicated to
confirm the first step results [6]. However, some SNPs
with p value around 10e-5 were disputable. Recently we
found two novel susceptibility genes YAP1 and LPP for
PCOS from these SNPs [7, 19]. So we selected two SNPs
with p value around 10e-5 in USP34 to validate whether
USP34 was associated with PCOS. No association was008940 genotype subgroups
TT(n = 130) P P adjusted
28.02 ± 3.66 0.046 −
25.517 ± 4.51 0.028 −
10.177 ± 5.44 0.957 0.500
53.72 ± 20.61 0.485 0.505
2.79 ± 2.32 0.653 0.399
d BMI in logistic regression
Table 4 Clinical and metabolic characteristics of PCOS cases in rs17008097 genotype subgroups
Characteristics CC(n = 548) GC(n = 531) GG(n = 139) P P adjusted
Age(years) 28.82 ± 3.79 28.44 ± 3.64 27.97 ± 3.73 0.044 −
BMI (kg/m2) 24.824 ± 4.26 25.287 ± 4.37 25.581 ± 4.51 0.106 −
LH (IU/L) 10.000 ± 6.12 9.963 ± 5.81 10.399 ± 5.61 0.746 0.393
T (ng/dl) 51.446 ± 20.14 51.897 ± 21.97 51.868 ± 20.69 0.940 0.904
HOMA-IR 2.642 ± 2.61 2.676 ± 2.19 2.773 ± 2.24 0.800 0.415
HOMA-IR: homeostasis model assessment; P adjusted: adjust the p value by age and BMI in logistic regression
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value around 10e-5 in GWAS were controvertible and
demanded for independent and large cohort of samples
for verification.
Although rs17008940 was not shown to be related to
PCOS, it might confer slight risk to the elevated BMI in
PCOS. However, this slightly association possibly results
from a selection bias derived from the patients and con-
trols being recruited in an infertility clinical center and
not from the general population. Hence, the results need
further validation. Higher BMI was one of the important
characteristics in PCOS and over 50 % PCOS women
were overweight or obesity [20, 21]. Consistent with our
results, previous studies also showed FTO and MC4R were
associated with increased BMI in PCOS subjects rather
than PCOS itself [22]. Abundant evidence have linked Wnt
signals to the regulation of adipogenesis [23, 24] and body
fat distribution [25]. For example, Christodoulides et al. re-
ported that mutation C256Y in WNT10B was associated
with overweight or obesity because the mutation was
unable to activate canonical Wnt pathway [26]; and
Choi et al. found that indirubin-3′-oxime (I3O), also an
activator of the Wnt signaling like USP34, inhibited the
development of obesity in high-fat diet fed mice [27].
Moreover, besides acting as an activator of Wnt pathway,
USP34 was also found to play a role in NFκB signal
regulation in T lymphocytes [28] and DNA damage re-
sponse control as it was the downstream of ATM/ATR
checkpoint kinase [29, 30]. USP34 may indirectly par-
ticipate in the pathophysiology of PCOS by elevating
BMI, but further studies were still needed to evaluate
the function of USP34 in the BMI increase among
PCOS women.
Some limitations of the present replication study
should be mentioned. First, the sample size of this rep-
lication study was relatively small (rs17008940, OR =
1.010; rs17008097, OR = 1.007) and this replication study
maybe not sufficient to detect the potential association be-
tween USP34 gene and PCOS. Second, only 2 SNPs were
chosen which may cause incomplete coverage of the
gene variations. Third, the recruited subjects were all
Han Chinese women and the result could not represent
other population.Conclusions
In conclusion, the present study found that polymor-
phisms of USP34 gene may not be associated with PCOS
women among Han Chinese population. SNPs with p
value around 10e-4 ~ 10e-6 in GWAS were disputable
and requiring replication studies for validation. Large well-
designed and population-based studies are warranted to
confirm our findings.
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